Velsipity
(Etrasimod)Phase 3Small molecule
PfizerEtrasimod is used to treat ulcerative colitis, an inflammatory bowel disease that causes inflammation and ulcers in the colon. It helps reduce symptoms like diarrhea, abdominal pain, and rectal bleeding by calming the immune system in the gut.[1] Velsipity is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Velsipity is one of 286 small molecule programs targeting Pyoderma Gangrenosum. It is currently in Phase 3.
13
Indications
25
Total Trials
8
Active Trials
285
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Fludara
SanofiPhase 3
Velsipity
PfizerPhase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Tagamet
DDT MedTech, LLC
Phase 3
Rocatinlimab
AmgenPhase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Fucidin
LEO PharmaPhase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis11 trials
Show 8 more trials
Colitis, Ulcerative3 trials
Medication2 trials
Atopic Dermatitis2 trials
6 more indications
Eosinophilic Esophagitis1 trial
Breastfeeding1 trial
ESS1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Etrasimod. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]